AXOGEN AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • January 25th, 2012 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Amended and Restated AXOGEN Nerve Tissue Processing Agreement (“Agreement”) consists of this signature page, the attached Terms and Conditions, and the Exhibits marked below. This Agreement authorizes LIFENET HEALTH to process human cadaveric tissue for AXOGEN. The term of this Agreement shall commence on the Effective Date and shall end as provided in the Terms and Conditions. For purposes of this Agreement, the “Effective Date” shall be the last date executed below. This Agreement becomes legally binding upon signature below by authorized representatives of the parties, and supersedes the AXOGEN Nerve Tissue Processing Agreement by and between the parties, dated November 16, 2007 (the “Original Agreement”).
AXOGEN AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
This Amended and Restated AXOGEN Nerve Tissue Processing Agreement (“Agreement”) consists of this signature page, the attached Terms and Conditions, and the Exhibits marked below. This Agreement authorizes LIFENET HEALTH to process human cadaveric tissue for AXOGEN. The term of this Agreement shall commence on the Effective Date and shall end as provided in the Terms and Conditions. For purposes of this Agreement, the “Effective Date” shall be the last date executed below. This Agreement becomes legally binding upon signature below by authorized representatives of the parties, and supersedes the AXOGEN Nerve Tissue Processing Agreement by and between the parties, dated November 16, 2007 (the “Original Agreement”).
THIRD AMENDMENT TO AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • March 15th, 2012 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus
THIS THIRD AMENDMENT (“Third Amendment”) to the Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, as amended on June 27, 2008 (“Amendment”), entered into by and among LifeNet Health (“LifeNet”) and AxoGen Corporation (the “Agreement”), is entered into between the parties on March 12, 2012 (“Third Amendment Effective Date”).
ExhibitNerve Tissue Processing Agreement • March 1st, 2017
*10.4.3 Third Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of March 12, 2012, by and between AxoGen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 15, 2012).
SECOND AMENDMENT TO AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • October 6th, 2011 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus
THIS SECOND AMENDMENT (“Second Amendment”) to the Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, as amended on June 27, 2008 (“Amendment”), entered into by and among LifeNet Health (“LifeNet”) and AxoGen Corporation (the “Agreement”), is entered into between the parties on August 9, 2011 (“Effective Date”).
FOURTH AMENDMENT TO AMENDED AND RESTATED NERVE TISSUE PROCESSING AGREEMENTNerve Tissue Processing Agreement • November 13th, 2014 • AxoGen, Inc. • Electromedical & electrotherapeutic apparatus
THIS FOURTH AMENDMENT (“Fourth Amendment”) to the Amended and Restated Nerve Tissue Processing Agreement dated February 27, 2008 as amended from time to time (the “Agreement”), is effective upon last signature hereto by and between LifeNet Health (“LIFENET Health”) and AxoGen Corporation (“AXOGEN”).
